STAT3 and non-small cell lung carcinoma: IL-6 is known to activate STAT3 in many NSCLC cells, but IL-6 treatment did not markedly increase the level of pY705-STAT3 in H1703 cells (Fig. S6A), most likely because STAT3 was already hyperactivated in these cells.